Status:

ENROLLING_BY_INVITATION

Physiologic and Functional Adaptations of Insulin Sensitive Tissues

Lead Sponsor:

Vanderbilt University Medical Center

Conditions:

Diabetes

Insulin Resistance

Eligibility:

All Genders

18+ years

Brief Summary

The long-term goal is to understand the mechanisms of intestinal nutrient sensing and signal relays to insulin sensitive tissues (adipose, skeletal muscle, liver) in humans. The investigators hypothes...

Detailed Description

Upper endoscopy (subset) * Intestinal biopsies will be obtained during scheduled upper endoscopy from the mid-duodenum and/or proximal jejunum. In the case that a patient requires an upper endoscopy ...

Eligibility Criteria

Inclusion

  • \- Scheduled for upper endoscopy, colonoscopy or metabolic and bariatric surgery, or liver transplantation at Vanderbilt University Medical Center.
  • Additional inclusion criteria for individuals scheduled for metabolic and bariatric surgery: Obese, ≥ 40 kg/m2 or ≥ 35 kg/m2 + one comorbidity (type 2 diabetes \[fasting blood glucose ≥ 120 mg/dL; HbA1C ≥ 6.5%\]; fatty liver disease, hypertension, cardiovascular disease, hyperlipidemia)
  • Additional inclusion criteria for individuals scheduled for liver transplantation: diagnosis of nonalcoholic liver disease or nonalcoholic steatohepatitis

Exclusion

  • Known history of intestinal diseases including, but not limited to, inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease) and celiac sprue.
  • Smoking \>7 cigarettes per day
  • Malabsorptive syndromes
  • Pregnant or breastfeeding
  • Additional exclusion criteria for patients undergoing endoscopy/colonoscopy:
  • Recent history of malignancy (\<5 years ago)
  • Previous lap band surgery
  • Established renal disease
  • Additional exclusion criteria for patients undergoing bariatric surgery:
  • Previous lap band, sleeve gastrectomy, or gastric bypass surgery
  • Recent history of malignancy (\< 5 years ago)
  • Established organ dysfunction
  • Additional exclusion criteria for patients undergoing liver transplantation:
  • Previous lap band, sleeve gastrectomy, or gastric bypass surgery
  • Alpha 1 anti-trypsin disease, Wilson's disease, viral hepatitis, alcoholic liver disease

Key Trial Info

Start Date :

February 13 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2028

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT03407833

Start Date

February 13 2018

End Date

February 1 2028

Last Update

December 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232